1. Home >
  2. Companies >
  3. Life Science >
  4. United States >
  5. North Carolina >
  6. G1 Therapeutics

G1 Therapeutics - Ownership and Business Overview

Life ScienceCompany

G1 Therapeutics Ownership

Who owns G1 Therapeutics?

G1 Therapeutics is owned by Pharmacosmos A/S. It was acquired on August 7, 2024.

G1 Therapeutics Business Overview

Where is G1 Therapeutics headquartered?

G1 Therapeutics is headquartered in Research Triangle Park, North Carolina.

What is G1 Therapeutics’ revenue?

G1 Therapeutics disclosed revenue of 83M USD for 2023 and 51M USD for 2022.

What sector is G1 Therapeutics in?

G1 Therapeutics is a life science company.

Life Science M&A Summary in 2024

Out of 60 sectors in the Mergr database, life science ranked 8 in number of deals in 2024. The largest life science acquisition in 2024 was Catalent - which was acquired by Novo Holdings A/S for $16.5B.

Subscribe to Mergr to view all 221 acquisitions of life science companies in 2024, including 25 acquisitions by private equity firms, and 196 by strategics.

G1 Therapeutics

G1 Therapeutics, Inc.

700 Park Offices Drive Suite 200,
Research Triangle Park, North Carolina 27709
United States,
(919) 213-9835
www.g1therapeutics.com

G1 Therapeutics is a commercial-stage oncology biopharmaceutical company developing and delivering next-generation therapies that improve the lives of those affected by cancer, including the Company’s first commercial product, COSELA (trilaciclib). G1 Therapeutics is based in Research Triangle Park, North Carolina.


Company Summary

SECTOR

Life Science

Revenue

83   63% 2023
51   65% 2022
31   32% 2021
45   2020
(millions of USD) Show More Show Less

 Subscribe to unlock this and 215,016
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More
Get Full Access

What's Mergr?

Mergr is a user-friendly database designed to simplify the complex world of private equity and M&A for busy professionals.

We created Mergr to eliminate the challenge of tracking company acquisitions, sales, and ownership, providing clear insights into investment firms and their activities. For example, explore a company's M&A activity, ownership history, and connections - organized to help you uncover opportunities and make informed decisions.

With Mergr, gain access to a comprehensive, interconnected web of transactions, investors, companies, and advisors - all in one place.

Mergr, the Easiest-to-Use PE and M&A DB

Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.7K Private Equity Firms
  • 208K M&A Transactions
  • 210K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.7K M&A Advisors
    (Investment Banks and Law Firms)
  • 81K M&A Contacts
    (PE and M&A Advisors)

What next?

Get Full Access

Full access to Mergr's investor, acquirer, and transaction data starts here.

Related Lists for G1 Therapeutics

Life Science Companies

Related Lists for Life Science Companies

Largest Life Science Companies , Acquisitive Life Science Companies , Recently Acquired Life Science Companies , Recently Sold Life Science Companies , Private Life Science Companies , Public Life Science Companies , Acquired Life Science Companies , PE Backed Life Science Companies
Mergr

Solution for

Product

Company

Legal